Skip Navigation


NDT Advance Access originally published online on August 5, 2006
Nephrology Dialysis Transplantation 2006 21(11):3180-3184; doi:10.1093/ndt/gfl383
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/11/3180    most recent
gfl383v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Magnasco, A.
Right arrow Articles by Alloatti, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magnasco, A.
Right arrow Articles by Alloatti, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Glucose infusion test (GIT) compared with the saline dilution technology in recirculation measurements

Alberto Magnasco1 and Sandro Alloatti2

1Renal Unit G. Gaslini Institute, Largo Gaslini 4, 16148 Genoa, Italy2Renal Unit, Aosta

Correspondence and offprint requests to: A. Magnasco. Email: alberto.magnasco{at}ospedale-gaslini.ge.it

Background. Glucose infusion test (GIT) is a new method to measure vascular access recirculation (R) based on basal glucose increase in the arterial blood line after a 20% glucose bolus (5 ml) into the venous chamber.

Methods. We compared GIT with the ultrasound dilution method (HD01, Transonic Systems Inc., USA) in a circuit reproducing in vitro the phenomenon of R. We repeated the comparison in 162 chronic haemodialysis patients (133 fistulae, 17 central venous catheters, 12 prosthetic grafts).

Results. In vitro, we determined the timing for C2 sampling: QB 200 ml/min, C2 16–20 s; QB 300 ml/min, C2 13–17 s; QB 400 ml/min, C2 9–12 s. GIT showed no false positives nor false negatives (100% specificity and sensitivity) while HD01 did not recognize three cases with R = 5% (91% sensitivity) and it yielded no false positive (100% specificity). The Bland–Altman analysis showed a bias of 0.2 ± 1.3% and 1.3 ± 2.9% for GIT and HD01, respectively. In vivo, only 16 out of 162 patients were found positive with both methods (GIT 13.5 ± 13%; HD01 16.3 ± 15%; P = NS) while three patients with minimal R (GIT 3.2%) were not recognized by HD01 although a low R peak was clearly evident and repeatable on the laptop plot. The Bland–Altman analysis showed an overall bias of 0.2 ± 1.7% to the limits of agreement = –3.1 and 3.6% (n = 162) and no correlation between the difference and the mean of positive tests. The pooled coefficient of variation of positive cases was 13.3 and 18.1% for GIT and HD01, respectively.

Discussion. Our in vitro study showed a good performance of GIT and its better sensitivity compared to HD01. These results were confirmed in vivo with only 3/162 discordant results due to a low R under the HD01 limit of detection (R = 5%). In conclusion, the GIT proved to be a very accurate screening test for R, with a very low threshold of detection. In addition, it is simple, user-friendly and inexpensive.

Keywords: dialysis; dialysis adequacy; dialysis efficiency; recirculation; vascular access


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.